Event Abstract

Back to Event

Omalizumab, a treatment alternative solar urticaria difficult to control

Ana M. Celis Henao1*, Catalina M. Gómez Henao1* and Ricardo Cardona Villa1
  • 1 Universidad de Antioquia, Colombia

Introduction: The solar urticaria is one of the rare types of urticaria characterized by intense itching, hives and rash in locations exposed to sunlight (UVA, UVB and visible light) with individual action spectra for each patient. The first line of treatment is non-sedating H1 antihistamines and sunscreens, which in severe cases are not enough to control symptoms. Few reports have described patients with inducible hives like solar urticaria with successful treatment with anti-IgE therapy. Objective: To describe a case of solar urticaria patient responded well to treatment with omalizumab. Methods: The case of a female patient of 23 years old with a history of solar urticaria, which has several episodes of anaphylaxis, handled with high doses of non-sedating antihistamines, antileukotriene and sunscreen without symptomatic remission with treatment described, whereby we decided to start omalizumab 300 mg every 15 days with control of cutaneous and systemic symptoms. Results: At 5 months into the omalizumab, the patient reported clinical improvement. With subsequent exposure to the sun without skin or systemic symptoms. There has been no adverse reaction to this drug application. Conclusion: The solar urticaria, in their form refractory, a disease with high impact on the quality of life of patients, not just for the poor response to first-line treatments but by one of its clinical manifestations, anaphylaxis, which endanger the patient's life, which makes it a therapeutic challenge where omalizumab is an alternative effective treatment

Acknowledgements

Allergy Clinic Group Universidad de Antioquia

References

References:
1. Spector SL, Tan RA. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007;99:190–193.
2. Metz M. et. al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticarial. Int Arch Allergy Immunol. 2011;154(2):177-80
3. Metz. M. et. al. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticarial. JAMA Dermatol. 2014 Mar;150(3):288-90.
4. Güzelbey O1 et. al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy. 2008 Nov;63(11):1563-5.
5. J. Sánchez, R. Ramírez. S. Diez, S. Sus, A. Echenique, M. Olivares, R. Cardona. Omalizumab beyond asthma. Allergol Immunopathol. 2012;40(5):306-315. Figure taken with permission from the author

Keywords: Omalizumab, Urticaria, Solar urticaria, difficult, Control

Conference: IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología, Medellin, Colombia, 13 Oct - 16 Oct, 2015.

Presentation Type: Poster Presentation

Topic: Allergy

Citation: Celis Henao AM, Gómez Henao CM and Cardona Villa R (2015). Omalizumab, a treatment alternative solar urticaria difficult to control. Front. Immunol. Conference Abstract: IMMUNOCOLOMBIA2015 - 11th Congress of the Latin American Association of Immunology - 10o. Congreso de la Asociación Colombiana de Alergia, Asma e Inmunología. doi: 10.3389/conf.fimmu.2015.05.00268

Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters.

The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated.

Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed.

For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions.

Received: 31 May 2015; Published Online: 14 Sep 2015.

* Correspondence:
Dr. Ana M Celis Henao, Universidad de Antioquia, Medellin, Colombia, amcelish@hotmail.com
Dr. Catalina M Gómez Henao, Universidad de Antioquia, Medellin, Colombia, catago13@hotmail.com